BioScale, a Cambridge, MA-based maker of life sciences research and diagnostics tools that analyze proteins, reports today it has nailed down a $25 million round of financing. China’s Morningside Venture led the new round, which included investments from the company’s previous backers New Science Ventures and WFD Ventures, both of which are located in New York City, as well as London-based F2 Ventures and individuals. BioScale, founded in 2002, reports that the new financing is intended to fund an expansion of sales and manufacturing of its protein analysis tools.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
